Sanofi to buy Regeneron once the CV launch is over?

Anonymous

Guest
I've been in a situation where my company actually acquired the other company we were co-promoting drugs with. Slashed the salesforce and kept a handful....Is there any risk to that happening to Regeneron? Little pharma gobbled up by big pharma?

Thoughts ?
 
























Dude, quit trolling. We have no idea and neither do you.

Not trolling...just getting thoughts. It's certainly something to consider if you are thinking about coming on board with Regeneron. It's legit but if you would rather talk about "what your favorite color is" because it's easier to talk about and what's mostly discussed here on CP, then so be it.

I know no one has any idea, but thought it might be an interesting topic to discuss. I for one would not want to come on board worried about working for Sanofi one day. That would suck. I think you would agree too and certainly would understand the concern.
 






If the product is successful, of course Sanofi will purchase. You have to be a complete idiot of you don't know that. If it isn't the blockbuster they hope it will be, then of course Sanofi won't bother.
 






As a former REGN employee I can confidently tell you that yes, Sanofi will buy REGN but, not until 2017. If you're already hired ask around and you will find out why...
 






Sanofi cannot attempt to buy Regeneron until 2022 (5 years after the co-promotion agreement ends in 2017) based on a "standstill agreement" filed with the SEC. Don't believe me, look it up. All of this is public record.
 












"Under the terms of the amended and restated agreement, Sanofi retains its right to acquire up to 30% of Regeneron's outstanding common stock and Class A stock and gains the right to nominate a single independent director to the Regeneron Board of Directors upon reaching 20% ownership of Regeneron's outstanding common stock and Class A stock. The new independent director must be approved by Regeneron's board based on Sanofi's proposals and not have any current or previous relationship with Sanofi. All shares of Regeneron's common stock owned by Sanofi now or in the future are subject to an amended "Lock-Up" provision that prohibits any sales through at least December 20, 2020 and imposes certain restrictions on the manner of sales thereafter. In addition, Sanofi has agreed to be bound by an amended voting agreement which specifies that Sanofi must vote its shares as recommended by Regeneron's board except in certain defined circumstances, and revised "standstill" provisions that continue to prohibit Sanofi from seeking to directly or indirectly exert control over Regeneron or acquiring more than 30% of Regeneron's outstanding common stock and Class A stock, except under certain specified conditions. Sanofi's current ownership of Regeneron is 15.8 million shares, representing approximately 16% of Regeneron's outstanding common stock and Class A stock."

Which means, if the aging white males that populate REGN's BoD decide they have cashed out to the level they expected, they can initiate the process that would result in Sanofi taking over REGN by the close of 2017... LS, GY and others aren't getting any younger. Which would you do, take a billion bucks and retire or become Sanofi Bridgewater North?